



“Grecian Odyssey”

53rd ANNUAL TIARA BALL

Chair: Sophia Mylona
November 18th, 2023
Bahia Mar Fort Lauderdale Beach Resort

The Royal Dames' Mission

It is our fundamental belief that man is not destined to die of cancer.
To this end, the Royal Dames of Cancer Research are dedicated to funding research to find a cure.

A Rich Tradition Since 1969

Since its inception by this philanthropic group of ladies more than 50 years ago, the Royal Dames have joined together with friends and guests for the Tiara Ball, our signature fundraising event. This spectacular annual charity ball, attended by community leaders throughout the tri-county area, is one of the most elegant galas of the season, creating an exciting and profitable evening for the benefit of cancer research. Through this and other events, the Royal Dames have raised almost 4 million dollars to aid, enrich and support valuable educational programs and life-saving cancer research.

Today we continue the efforts to support the scientific programs at the Rumbaugh-Goodwin Institute for Cancer Research at Nova Southeastern University's Center for Collaborative Research and the education program and activities of other Florida based not-for-profit organizations for research in the state of Florida.

We are now planning the **53rd Annual Tiara Ball, “Grecian Odyssey,”** chaired by Sophia Mylona. This is our largest and most significant fundraiser of the year and is sure to be a spectacular evening. **This will take place November 18th, 2023 at the Bahia Mar Fort Lauderdale Beach Resort.**

We look forward to your support in this endeavor!

Sponsorship Levels

	Presenting Name	Guests at Tiara Ball	Premium Champagne	Butler Service	VIP Parking	Expedited Check-In	Journal Recognition	Invitation to Underwriter Party	Social Media Recognition	Name in Pre- and Post-Media	Name in Website Publicity	Page in Newsletter	Logo/Name in E-mail Publicity
<i>Double Diamond</i> \$100,000 +	●	24	●	●	Sponsor + Guests	●	Inside Front Cover + 2 Pages	10	●	●	●	●	●
<i>Diamond Politaire</i> \$75,000 +		20	●		Sponsor	●	Back Cover + 2 Pages	8	●	●	●	●	●
<i>Diamond</i> \$50,000 +		12	●		Sponsor	●	Inside Back Cover + 2 Pages	6	●	●	●	●	
<i>Platinum</i> \$25,000 +		10					2 Pages	4	●	●	●	●	
<i>Gold</i> \$15,000 +		10					2 Pages	2	●	●	●		
<i>Silver</i> \$10,000 +		6					2 Pages	2	●		●		
<i>Bronze</i> \$5,000 +		4					1 Page	2	●		●		
<i>Copper</i> \$2,500 +		2					1 Page	2	●		●		

53rd Annual Tiara Ball Sponsorship & Underwriting Opportunities

SUBMISSION PAGE 1 OF 2

All Event Sponsors and Underwriters will receive acknowledgements in the Commemorative Journal as well as various credits, such as signage at the Tiara Ball, kick-off events and press leading up to the Ball, time permitting.

(Please Select Your Contribution Preference)

- | | |
|---|---|
| <input type="checkbox"/> Double Diamond Sponsor \$100,000 and above | <input type="checkbox"/> Printing Underwriter \$13,000 and above |
| <input type="checkbox"/> Diamond Solitaire Sponsor \$75,000 and above | <input type="checkbox"/> Entertainment Underwriter \$8,000 and above |
| <input type="checkbox"/> Diamond Sponsor \$50,000 and above | <input type="checkbox"/> Décor Underwriter \$5,000 and above |
| <input type="checkbox"/> Platinum Sponsor \$25,000 and above | <input type="checkbox"/> Wine & Champagne Underwriter \$3,000 and above |
| <input type="checkbox"/> Gold Sponsor \$15,000 and above | <input type="checkbox"/> Cocktail Hour Underwriter \$2,500 and above |
| <input type="checkbox"/> Silver Sponsor \$10,000 and above | <input type="checkbox"/> Photography Underwriter \$2,500 and above |
| <input type="checkbox"/> Bronze Sponsor \$5,000 and above | <input type="checkbox"/> Valet Parking Underwriter \$1,000 and above |
| <input type="checkbox"/> Copper Sponsor \$2,500 and above | <input type="checkbox"/> Postage Underwriter \$1,000 and above |

Commemorative Journal

IMPORTANT: The Internal Revenue Service requires that ads placed in non-profit journals contain a message of support for the organization. Ads should NOT be solely a commercial advertisement.

We will send you a specific guideline upon request.

Please select your advertising preference(s) below.

Journal Page	Trim Size 8.5 x 11 Bleed Size	Live Area Non-Bleed	Price	Quantity
Outside Back Cover (1)	8.75 x 11.25	7.5" x 10"	\$3,000	<input type="checkbox"/> (1 available)
Inside Back Cover (1)	8.75 x 11.25	7.5" x 10"	\$2,000	<input type="checkbox"/> (1 available)
Full-Page Color		7.5" x 10"	\$600	<input type="checkbox"/>
Full-Page Black / White		7.5" x 10"	\$375	<input type="checkbox"/>
Half-Page Color		7.5" x 4.875"	\$375	<input type="checkbox"/>
Special Restaurant Half -Page		7.5" x 4.875"	\$300	<input type="checkbox"/>

PLEASE SUBMIT THIS PAGE WITH YOUR PAYMENT INFORMATION ON THE FOLLOWING PAGE

PAYMENT SUBMISSION FORM FOR SPONSORSHIP, UNDERWRITING AND JOURNAL MESSAGES

SUBMISSION PAGE 2 OF 2

DEADLINE FOR JOURNAL RECOGNITION IS SEPTEMBER 22, 2023

Ad Materials: (check one) Enclosed Will email Will mail Please create ad for me*
To Provide: (check one) .pdf of Ad Digital Photo & Text* Print Photo & Text* Text only*

* We will be happy to design your journal page free of charge. The Royal Dames does not guarantee placement of ads in the Journal if payment and/or ad copy is received after September 22, 2023.

Name (as to be recognized): _____

Contact Name: _____

Billing Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ Email: _____

Enclosed is my check for \$ _____ payable to: Royal Dames of Cancer Research, Inc.

Please charge my: VISA _____ Master Card _____ AMEX _____

A \$10 surcharge will be added to all credit card payments.

Cardholder Name: _____

Account #: _____ Exp. Date: _____

Security Code _____ Amount to be charged: \$ _____ Zip Code _____

Signature: _____ Phone: _____

We must receive your 2-page order form with payment along with your finished journal submission or photograph(s), and copy (text).
There is no charge for designing the journal page for you.

Please email digital materials - a CMYK pdf of completed ad or text and high resolution (300 dpi photos) to Gloria Jacaruso at royaldamesads@gmail.com.

Printed materials can be mailed to:

Gloria Jacaruso at 43 N. Federal Hwy., Pompano Beach, FL 33062

Payments can be mailed to:

Jaime Shlimbaum at 206 NE 16th Ave Apt #1, Fort Lauderdale, FL 33301

Telephone inquiries: 631-487-7381

For sponsorship or underwriting information, please contact

Carole Nugent 954-554-7855, clnugent213@yahoo.com

IMPORTANT: Please provide the name and address for your Tiara Ball invitation:

NAME: _____

ADDRESS: _____

EMAIL: _____ PHONE: _____

Limited ballroom seating. Table placement is subject to availability with preference based on donation level.

A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER SERVICES BY CALLING 1-800-435-7352 TOLL-FREE WITHIN THE STATE. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE.

NSU Rumbaugh-Goodwin Institute for Cancer Research Project Summary (as of 2023)

NSU Rumbaugh-Goodwin Institute for Cancer Research (RGI), under the leadership of Appu Rathinavelu, Ph.D., institute director, has earned its reputation of a technology leader in anti-angiogenesis (the inhibiting of new blood vessel formation) applied to treating cancer. Below is a summary of current and planned projects:

BACKGROUND

RGI discovered the anti-angiogenic use of F16 and JFD molecules in 2010 and these discoveries were patented in 2011. The original discovery of the F16 and JFD lead molecules was done in collaboration with scientists from the Lombardi Cancer Center of Georgetown University. Currently, NSU has established a Non-disclosure Agreement (NDA) with Catalent Pharma Solutions to create injectable formulations for our F16 and JFD that can be used in humans during Phase I clinical trials.

GLIOBLASTOMA PROJECT

The Glioblastoma project is RGI's highest priority as it addresses a real-world clinical unmet need.

The Glioblastoma Project refers to the use of the injectable F16, which NSU funded and patented six patents for the treatment of breast, colorectal, lung and ovarian cancers. The patent for treating glioblastoma is pending approval. Glioblastoma is a difficult brain cancer to treat, however, RGI researchers discovered that F16 is a drug that inhibits new blood vessel growth in cancer (tumors).

OTHER IMPORTANT NSU/RGI PROJECTS

PEDIATRIC NEUROBLASTOMA PROJECT

In addition to the Glioblastoma treatment, RGI has also initiated the testing of F16 and JFD for the treatment of Neuroblastoma, a devastating cancer that occurs in children. Neuroblastoma also thrives because of new vessel formation that supplies oxygen and nutrients to the blood, enabling the cancerous cells to spread to other vital organ systems. Screening of the F16, JFD, and its analogs for treating Neuroblastoma is ongoing which will help us to complete the pre-clinical evaluation of the lead compound by the end of this year (2023).

NEUROFIBROMA PROJECT

Neurofibromatosis, also known as Type 2 Neurofibroma (NF2), is a condition with an occurrence frequency of 1 in 25 – 33,000. The NF2 patients may develop multiple tumors in the cranial, spinal, and peripheral nerves alongside tumors in the spinal cord. Currently, the FDA approved drug Avastin is used for controlling tumor growth and to improve hearing in patients with NF2. Since the RGI drugs F16 and JFD also show anti-angiogenic effects similar to Avastin, the Institute has initiated a new project that will be running alongside of the Pediatric Neuroblastoma project.

PERIPHERAL NEUROPATHY PROJECT

Chemotherapy drugs can induce a debilitating side-effect called Chemotherapy Induced Peripheral Neuropathy (CIPN). Development of CIPN causes severe pain and can affect patients' abilities to walk, write, or even button a shirt. CIPN can last for weeks, months, or even years after chemotherapy treatment is done. In the most severe cases of CIPN, patients experience changes in heart rate and blood pressure, trouble breathing, paralysis, and organ failure.

Early intervention of CIPN may save the lives of many cancer patients. The RGI of NSU launched research for finding new biomarkers in the blood and epigenetic biomarkers from the DNA of cancer patients through liquid biopsy approach. RGI has begun testing 50 Multiple Myeloma cancer patients who are being treated at the Cleveland Clinic of Florida in 2023. Once the biomarkers for detecting the very beginning of CIPN are discovered, RGI will expand this study to 200 more patients with other types of cancers.

MELANOMA PROJECT

The National Cancer Institute estimates there are more than 900,000 people living with melanoma in the US. Melanoma is one of the major cancers that is found in 'Sunny Florida'. Despite recent advances in melanoma drug discovery, the average overall survival for patients with late-stage metastatic melanoma is less than 3 years. Instances of complete response are very rare; therefore, more life-prolonging therapies are needed.

Recent *in vivo* proof-of-principle efficacy and toxicity studies using small molecules discovered by RGI demonstrate that spliceosomal proteins hnRNPH1 and H2 (H1/H2) can be targeted without overt toxicity to induce melanoma-specific cell death.

Based on these considerations, RGI hypothesizes that targeting of H1/H2 could be a much needed and effective broad-spectrum melanoma therapy.

ORGANIZATIONAL COLLABORATIONS (current and previous) include:

- Cleveland Clinic of Florida (ongoing): Collaborative agreement between RGI and Cleveland Clinic of Florida for discovering biomarkers using a Liquid Biopsy strategy for detecting Chemotherapy Induced Peripheral Neuropathy. Testing of human samples began in March 2023.
- Miami Cancer Institute, MCI (ongoing): In 2022, RGI established a collaboration with MCI to determine the cellular basis of prostate cancer disparities among different ethnic groups.
- University of Miami (ongoing): Dr. James E. Hoffman of the University of Miami Sylvester Comprehensive Cancer Center is serving as a collaborator and advisor on RGI's CIPN project. The project analyzes human samples for biomarker discovery.
- Moffitt Cancer Center Florida (ongoing): RGI Scientist Dr. Dmitriy Minond is collaborating with Keiran Smalley, Ph.D. of Moffitt Cancer Center Florida. The two are jointly publishing papers and applying, as collaborators, for grant funding.
- Mayo Clinic in Rochester, Minnesota (2015): In 2015, RGI scientists engaged with scientists at the Mayo Clinic to study the Clinic's animal models for brain cancer (glioblastoma) research with the goal of recreating the model at the NSU Center for Collaborative Research
- Lombardi Cancer Center at Georgetown University (2010): RGI originally discovered the anti-angiogenic use of F16 and JFD molecules in 2010 resulted from a collaboration with the Lombardi Cancer Center at Georgetown University. The proposed therapeutic applications for the F16 and JFD molecules were patented by RGI in 2011.

SILENT AUCTION DONOR FORM

SUBMISSION PAGE

DEADLINE FOR JOURNAL RECOGNITION IS SEPTEMBER 22, 2023

PLEASE COMPLETE ALL SECTIONS OF THIS FORM AND MAIL, OR EMAIL BACK TO US

Date Donated: _____ Date Item Received: _____

Full Item Description: _____

Fair Market Value: \$ _____ Minimum Bid: \$ _____ (Donor Estimate)

Royal Dames reserves the right to set the minimum bid but the Donor Estimate will be taken into account.

Item is a service: (Certificate or Letter must be enclosed)

Item is enclosed

Item to be picked up from donor

Item to be shipped tracking number will be sent

Restrictions: List any restrictions such as expiration dates, black-out dates, etc.

Donor Name: _____

Donor Business Name: _____

Donor Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ Email: _____

Donor Signature: _____

Please call to arrange for item pick up or delivery. Item deliveries must be scheduled.

Source: Enter the name of the person who procured the donation

PLEASE MAIL OR EMAIL COMPLETED FORMS TO
ROYAL DAMES C/O KATIE MASUCCI - KMM27@NTRS.COM
2400 N.E. 37TH DRIVE, FORT LAUDERDALE, FL 33308
TELEPHONE INQUIRIES: 561-531-1148

